Status:

ACTIVE_NOT_RECRUITING

STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study

Lead Sponsor:

Nippon Medical School

Collaborating Sponsors:

Daiichi Sankyo Co., Ltd.

Conditions:

Ischemic Stroke

Atrial Fibrillation Non-Rheumatic

Eligibility:

All Genders

20-85 years

Phase:

PHASE3

Brief Summary

Catheter ablation (CA) has been reported to reduce risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) in retrospective studies, but risk and benefit of CA has not been well elucida...

Detailed Description

In patients with NVAF, stroke is an independent risk factor for a subsequent cerebral infarction. Although anticoagulant therapy can effectively reduce thromboembolic events, the reported annual recur...

Eligibility Criteria

Inclusion

  • Age ≥20 or ≤85 years at time of giving informed consent
  • Nonvalvular atrial fibrillation
  • History of stroke in previous 6 months
  • Current or planned treatment with edoxaban
  • Modified Rankin scale ≤3

Exclusion

  • Symptomatic paroxysmal AF resistant to anti-arrhythmic drugs
  • Presence of left atrial thrombus and left atrial appendage on transthoracic echocardiography, computed tomography or magnetic resonance imaging
  • Unable to take anticoagulation therapy for any reason, including tendency to bleed or considered at high risk for bleeding from anticoagulation therapy.
  • Presence of severe renal disorder (estimated creatinine clearance \<30 mL/min by Cockroft-Gault equation)
  • Previous CA or surgical intervention for AF
  • History of treatment with a left atrial appendage closure device
  • Left atrial diameter ≥55 mm on transthoracic echocardiography
  • Ejection fraction ≤35% on transthoracic echocardiography
  • Persistent AF for ≥10 years
  • Pregnant or possibility of pregnancy
  • Unlikely to complete the study, such as due to progressive malignant tumor
  • Participating or planning to participate in another clinical trial
  • Unwilling to participates
  • Judged as incompatible for the study by the investigators

Key Trial Info

Start Date :

April 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 31 2026

Estimated Enrollment :

251 Patients enrolled

Trial Details

Trial ID

NCT03777631

Start Date

April 1 2018

End Date

March 31 2026

Last Update

November 15 2023

Active Locations (46)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 12 (46 locations)

1

Ichinomiyanishi Hospital

Aichi, Japan

2

Hirosaki Stroke and Rehabilitation Center

Aomori, Japan

3

Hirosaki University Hospital

Aomori, Japan

4

Kimitsu Chuo Hospital

Chiba, Japan